Healthcare
Another well-timed short from Tom Chanos - having initiated coverage at $157 (Jun 21), the shares are currently languishing at $93. Tom describes NVRO as a one product company, who's product doesn't work! The whole premise that the Omnia is something new and exciting is laughable and smacks of a company in desperation mode. Competition (including a new, superior device from Saluda), pricing wars, takeover prospects (or lack of!) and insurers cracking down on approvals are all covered in Tom’s 45-page report.
Edition: 124
- 26 November, 2021